Clinical trialNCT02210559CompletedPhase 1/PHASE2Interventional

A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer

SponsorKyntra BioEnrollment37Pancreatic Cancer (Unresectable)

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This is a Phase 1/2 trial to evaluate the safety, tolerability, and efficacy of FG-3019 administered with gemcitabine and nab-paclitaxel in the treatment of locally advanced, unresectable pancreatic cancer.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Vincent Picozzi, MD
Virginia Mason Medical Center - Benaroya Research Institute
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Honorhealth Research Institute
Scottsdale, Arizona, United States
University of California, Los Angeles
Los Angeles, California, United States
Georgetown University - Medstar Health Research Institute
Washington D.C., District of Columbia, United States
Mayo Clinic Florida
Jacksonville, Florida, United States
Ochsner Clinic Foundation
New Orleans, Louisiana, United States
Virginia Piper Cancer Institute
Minneapolis, Minnesota, United States
Thomas Jefferson University
Philadelphia, Pennsylvania, United States
Virginia Mason Medical Center - Benaroya Research Institute
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

FG-3019Gemcitabine →Paclitaxel →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jul 2014
Primary completion: 15 Dec 2021
Completion: 15 Dec 2021
Last update posted: 2 Mar 2023
Registered enrollment: 37
Registry id: NCT02210559

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.